Share Twitter LinkedIn Facebook Email Rajat Bannerji, MD, PhD Associate Professor of Medicine Division of Hematology Oncology Robert Wood Johnson Medical School Rutgers, The State University of New Jersey Discusses Phase 1 Study Of REGN1979 At The 60th ASH Annual Meeting on Dec 1, 2018.
FDA Approves Adcetris / brentuximab vedotin + lenalidomide & rituximab in relapsed or refractory LBCL: Could This Change Standard Care? Lymphoma 2 Mins Read
2024 Update on Lymphoma Treatment: Navigating the Latest Advances – Elizabeth Brem, MD [38 Slides] Hodgkin Lymphoma 4 Mins Read
FDA Grants Accelerated Approval to Zanubrutinib (Brukinsa) for Relapsed or Refractory Follicular Lymphoma Lymphoma 2 Mins Read